02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
21:31 , Nov 18, 2016 |  BC Week In Review  |  Financial News

BioPorto completes private placement

BioPorto raised DKK21.8 million ($3.1 million) through the sale of 12.9 million shares at DKK1.69 in a private placement to existing investors and institutional investors. BioPorto Diagnostics A/S (CSE:BIOPOR), Gentofte, Denmark ...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

NGAL Test regulatory update

BioPorto said it will continue to seek FDA approval of its NGAL Test to detect acute kidney injury following discussions with the agency and anticipates “approval within 18-24 months.” In late May, FDA rejected the...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Clinical News

NGAL Test regulatory update

FDA rejected a regulatory application from BioPorto for the NGAL Test to detect acute kidney injury. According to the company, FDA rejected it because the application “did not provide adequate clinical and analytical data to...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Financial News

BioPorto Diagnostics completes private placement

BioPorto Diagnostics A/S (CSE:BIOPOR), Gentofte, Denmark   Business: Diagnostic, Antibodies   Date completed: 2015-08-31   Type: Private placement   Raised: DKK28.1 million ($4.3 million)   Shares: 11.7 million   Price: DKK2.40   Shares after offering:...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

NGAL Test: Clinical trial completed enrollment

BioPorto completed enrollment of 250 ICU patients in a blinded, U.S. clinical trial comparing its NGAL Test vs. clinical diagnosis of AKI as determined by Kidney Disease Improving Global Outcomes (KDIGO) guidelines. BioPorto Diagnostics A/...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Company News

BioPorto Diagnostics management update

BioPorto Diagnostics A/S , Gentofte, Denmark   Business: Diagnostic, Antibodies   Departing: Otto Rasmussen as CFO, effective Jan. 31; he is succeeded by Birgitte Svendsen, CEO of Pecunia Consult ApS, as interim CFO  ...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

BioPorto Diagnostics diagnostic news

BioPorto said the European Patent Office ruled that BioPorto's European Patent No. EP1831699 doesn't meet the "requirements for adequate description" and is invalid. The patent covers a method of diagnosing renal disorders by applying a...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Company News

BioPorto Diagnostics, Thermo Fisher, Abbott diagnostic news

BioPorto announced agreements with two of the four companies with objections to the company's European Patent No. EP1831699, which covers a method of diagnosing renal disorders by applying a cutoff when measuring the concentration of...